Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1474 | Extracorporeal membrane oxygenation Wiki | 0.50 |
| drug1432 | Evolocumab Wiki | 0.25 |
| drug2916 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.05 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.04 |
| D055371 | Acute Lung Injury NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 4 clinical trials
This study is designed to assess pharmacokinetics and pharmacodynamics of evolocumab and alirocumab across an appropriate dose range to inform clinical trial operating characteristics for future clinical pharmacology pharmacodynamics similarity studies. This is a randomized, placebo-controlled, single-dose, parallel arm study in 72 healthy subjects assigned to one of four dose groups (low, intermediate low, intermediate high, and high) of each drug (evolocumab and alirocumab ) or placebo.
Description: The values and variability of AUEC for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Area under effect curve (AUEC) for LDL-C for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of maximum change from baseline for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum change from baseline for LDL-C for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of AUEC for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: AUEC for Apolipoprotein B (ApoB) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of maximal difference at a single time-point for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum change from baseline for apoB for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of Cmax at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum concentration (Cmax) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of AUC at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Area under the curve (AUC) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: Model parameters (Emax) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.
Measure: Pharmacodynamic model parameters (maximum effect [Emax]) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: Model parameters (EC50) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.
Measure: Pharmacodynamic model parameters (half maximum effect concentration [EC50]) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armThis study is designed to assess pharmacokinetics and pharmacodynamics of evolocumab and alirocumab across an appropriate dose range to inform clinical trial operating characteristics for future clinical pharmacology pharmacodynamics similarity studies. This is a randomized, placebo-controlled, single-dose, parallel arm study in 72 healthy subjects assigned to one of four dose groups (low, intermediate low, intermediate high, and high) of each drug (evolocumab and alirocumab ) or placebo.
Description: The values and variability of AUEC for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Area under effect curve (AUEC) for LDL-C for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of maximum change from baseline for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum change from baseline for LDL-C for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of AUEC for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: AUEC for Apolipoprotein B (ApoB) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of maximal difference at a single time-point for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum change from baseline for apoB for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of Cmax at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum concentration (Cmax) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of AUC at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Area under the curve (AUC) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: Model parameters (Emax) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.
Measure: Pharmacodynamic model parameters (maximum effect [Emax]) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: Model parameters (EC50) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.
Measure: Pharmacodynamic model parameters (half maximum effect concentration [EC50]) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armThis study is designed to assess pharmacokinetics and pharmacodynamics of evolocumab and alirocumab across an appropriate dose range to inform clinical trial operating characteristics for future clinical pharmacology pharmacodynamics similarity studies. This is a randomized, placebo-controlled, single-dose, parallel arm study in 72 healthy subjects assigned to one of four dose groups (low, intermediate low, intermediate high, and high) of each drug (evolocumab and alirocumab ) or placebo.
Description: The values and variability of AUEC for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Area under effect curve (AUEC) for LDL-C for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of maximum change from baseline for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum change from baseline for LDL-C for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of AUEC for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: AUEC for Apolipoprotein B (ApoB) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of maximal difference at a single time-point for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum change from baseline for apoB for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of Cmax at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum concentration (Cmax) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of AUC at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Area under the curve (AUC) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: Model parameters (Emax) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.
Measure: Pharmacodynamic model parameters (maximum effect [Emax]) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: Model parameters (EC50) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.
Measure: Pharmacodynamic model parameters (half maximum effect concentration [EC50]) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armThis study is designed to assess pharmacokinetics and pharmacodynamics of evolocumab and alirocumab across an appropriate dose range to inform clinical trial operating characteristics for future clinical pharmacology pharmacodynamics similarity studies. This is a randomized, placebo-controlled, single-dose, parallel arm study in 72 healthy subjects assigned to one of four dose groups (low, intermediate low, intermediate high, and high) of each drug (evolocumab and alirocumab ) or placebo.
Description: The values and variability of AUEC for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Area under effect curve (AUEC) for LDL-C for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of maximum change from baseline for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum change from baseline for LDL-C for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of AUEC for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: AUEC for Apolipoprotein B (ApoB) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of maximal difference at a single time-point for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum change from baseline for apoB for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of Cmax at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Maximum concentration (Cmax) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: The values and variability of AUC at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab
Measure: Area under the curve (AUC) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: Model parameters (Emax) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.
Measure: Pharmacodynamic model parameters (maximum effect [Emax]) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armDescription: Model parameters (EC50) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.
Measure: Pharmacodynamic model parameters (half maximum effect concentration [EC50]) for evolocumab and alirocumab Time: 42, 56, or 84 days, depending on treatment armAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports